Supreme Court Slams 'Carnage' of Cancer Drug Mark-Ups, Demands Pricing Overhaul

The Supreme Court of India on Thursday strongly criticized the steep mark-ups on cancer drugs and other essential medicines, describing the pricing disparity as 'carnage'. The court's remarks came while hearing a petition that seeks the apex court's intervention to regulate the prices of drugs, medical equipment, and generic medicines, making them more affordable for the common man.

The petitioners argued that the current pricing mechanism allows pharmaceutical companies to charge exorbitant rates, putting life-saving cancer drugs out of reach for many. The court observed that the disparity between the cost of production and the retail price is alarming and needs urgent attention. It questioned the government's role in regulating drug prices and sought explanations on the existing pricing framework.

The Supreme Court's intervention could lead to significant reforms in India's pharmaceutical pricing policy, potentially impacting the profitability of drug manufacturers but improving access to affordable healthcare. The government may now be compelled to review the National Pharmaceutical Pricing Authority's (NPPA) mechanisms and consider stricter price controls on essential medicines. The next hearing is expected to address the government's response and potential remedies.